Adrenaline Auto‐Injector Prescribing in Primary Care in England: An Analysis of Non‐Standard Dosing
Clinical & Experimental Allergy · 2026-01 · 56 (1) · 30-40
DOI: 10.1111/cea.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 02.11.2025. Verfasst von Louise J Michaelis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. Hauptthemen laut MEDLINE: Epinephrine, Anaphylaxis, Primary Health Care, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The recommended first‐line treatment for anaphylaxis in the community is intramuscular injection of adrenaline. The treatment is a standardised dose of either a 150 μg or a 300 μg adrenaline auto‐injector (AAI) device depending upon the patient's weight. Currently, no standardised mechanisms exist to transition patients onto the higher 300 μg dose when they reach 25–30 kg (depending upon the manufacturer).
Methods
We undertook analysis of NHS prescriptions data dispensed in the community in England to identify rates of non‐standard AAI dose prescribing. Non‐standard prescribing is defined as patients who are likely to have exceeded the 25–30 kg threshold but still received a 150 μg dose. Data were limited to the most recent AAI prescription for an individual patient that occurred in the last 2 years (December 2022–2024). Patient weight at the time of prescribing was approximated using an age‐to‐weight correlation model. AAI recommended switching weights, based on device metadata, were compared to the patients' approximated weight to identify non‐standard prescribing. Statistical comparison between rates of non‐standard prescribing and patient deprivation was computed using Kendall's Tau correlation coefficient. A complementary analysis to identify patients who received a 300 μg dose but were likely under the 25–30 kg threshold was also carried out.
Results
Overall, 46,999 patients were identified as having received a 150 μg strength injector in their most recent AAI prescription; of these, over 95% received two or more devices in line with national guidance. Estimates based on age for weight growth centiles show that between 9480 (20.2%) and at least 1747 (3.7%) of those prescribed a 150 μg autoinjector were likely to exceed the weight threshold for this dose. Using a Resuscitation Council UK guideline of age 6 years for switching to a 300 μg dose, the estimated proportion prescribed a non‐standard AAI dose increases to 23,059 patients (49.1%). Estimated rates of non‐standard AAI prescribing were found to be higher in areas of England with the most deprivation. Conservative estimates found only 67 children likely under 25 kg and 330 children likely under 30 kg who received a 300 μg dose.
Conclusions
This analysis of community AAI prescriptions in England suggests that underdosing of AAI prescriptions in children and adults is not uncommon. Healthcare professionals with patients at risk of anaphylaxis should review whether patients prescribed AAI devices have the appropriate device for their weight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
- Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.
- NHS Business Services Authority, Newcastle Upon Tyne, UK.
- Gateshead Health NHS Foundation Trust, Queen Elizabeth Hospital, Gateshead, UK.
ORCID-Profile: Louise J Michaelis, Thomas Owen, Andrew D Bright
Zitieren
APA
Michaelis, L. J., Owen, T., Bright, A. D., & Sherwin-Robson, L. (2026). Adrenaline Auto‐Injector Prescribing in Primary Care in England: An Analysis of Non‐Standard Dosing. Clinical & Experimental Allergy, 56(1), 30-40. https://doi.org/10.1111/cea.70163
Vancouver
Michaelis LJ, Owen T, Bright AD, Sherwin-Robson L. Adrenaline Auto‐Injector Prescribing in Primary Care in England: An Analysis of Non‐Standard Dosing. Clinical & Experimental Allergy. 2026;56(1):30-40. doi:10.1111/cea.70163
BibTeX
@article{Michaelis2026,
author = {Michaelis, Louise J and Owen, Thomas and Bright, Andrew D and Sherwin-Robson, Lucy},
title = {Adrenaline Auto‐Injector Prescribing in Primary Care in England: An Analysis of Non‐Standard Dosing},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {1},
pages = {30--40},
doi = {10.1111/cea.70163}
}
EUVIMED